Atara Biotherapeutics, Inc. (ATRA)
ATRA Stock Price Chart
Explore Atara Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ATRA price movements and trends.
ATRA Company Profile
Discover essential business fundamentals and corporate details for Atara Biotherapeutics, Inc. (ATRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2014
Employees
153.00
Website
https://www.atarabio.comCEO
Anhco Nguyen
Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
ATRA Financial Timeline
Browse a chronological timeline of Atara Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.32, while revenue estimate is $550.00k.
Earnings released on 12 May 2026
EPS came in at -$0.29 surpassing the estimated -$0.33 by +12.00%, while revenue for the quarter reached $516.00k , missing expectations by -82.21%.
Earnings released on 16 Mar 2026
EPS came in at -$0.25 falling short of the estimated -$0.09 by -177.78%, while revenue for the quarter reached $1.64m , missing expectations by -51.17%.
Earnings released on 12 Nov 2025
EPS came in at -$0.32 surpassing the estimated -$0.83 by +61.45%, while revenue for the quarter reached $3.45m , beating expectations by +393.29%.
Earnings released on 11 Aug 2025
EPS came in at $0.19 surpassing the estimated -$0.32 by +159.38%, while revenue for the quarter reached $17.58m , beating expectations by +876.39%.
Earnings released on 15 May 2025
EPS came in at $3.50 surpassing the estimated -$3.07 by +214.01%, while revenue for the quarter reached $98.15m , beating expectations by +2.18k%.
Earnings released on 7 Mar 2025
EPS came in at -$1.19 surpassing the estimated -$3.82 by +68.85%, while revenue for the quarter reached $32.75m , beating expectations by +59.12%.
Earnings released on 12 Nov 2024
EPS came in at -$2.93 surpassing the estimated -$3.77 by +22.28%, while revenue for the quarter reached $40.19m , beating expectations by +21.44%.
Earnings released on 12 Aug 2024
EPS came in at -$3.10 falling short of the estimated -$1.25 by -148.00%, while revenue for the quarter reached $28.64m , missing expectations by -28.38%.
Stock split effective on 20 Jun 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2024
EPS came in at -$5.75 surpassing the estimated -$9.25 by +37.84%, while revenue for the quarter reached $27.36m , beating expectations by +10.80%.
Earnings released on 28 Mar 2024
EPS came in at -$14.00 surpassing the estimated -$15.25 by +8.20%, while revenue for the quarter reached $4.25m , missing expectations by -63.19%.
Earnings released on 1 Nov 2023
EPS came in at -$16.50 falling short of the estimated -$15.75 by -4.76%, while revenue for the quarter reached $2.14m , missing expectations by -55.08%.
Earnings released on 8 Aug 2023
EPS came in at -$17.00 falling short of the estimated -$16.25 by -4.62%, while revenue for the quarter reached $957.00k , missing expectations by -74.62%.
Earnings released on 8 May 2023
EPS came in at -$18.00 falling short of the estimated -$10.00 by -80.00%, while revenue for the quarter reached $1.23m , missing expectations by -96.00%.
Earnings released on 8 Feb 2023
EPS came in at -$18.00 falling short of the estimated -$15.25 by -18.03%, while revenue for the quarter reached $221.00k , missing expectations by -99.35%.
Earnings released on 8 Nov 2022
EPS came in at -$20.50 falling short of the estimated -$19.50 by -5.13%, while revenue for the quarter reached $4.46m , missing expectations by -13.14%.
Earnings released on 8 Aug 2022
EPS came in at -$7.75 surpassing the estimated -$22.75 by +65.93%, while revenue for the quarter reached $51.58m , beating expectations by +654.35%.
Earnings released on 5 May 2022
EPS came in at -$21.75 surpassing the estimated -$24.50 by +11.22%, while revenue for the quarter reached $7.31m , beating expectations by +26.38%.
Earnings released on 28 Feb 2022
EPS came in at -$24.00 falling short of the estimated -$15.00 by -60.00%, while revenue for the quarter reached $7.55m , missing expectations by -75.94%.
Earnings released on 4 Nov 2021
EPS came in at -$22.50 surpassing the estimated -$23.00 by +2.17%, while revenue for the quarter reached $5.37m , beating expectations by +53.87%.
Earnings released on 9 Aug 2021
EPS came in at -$22.75 falling short of the estimated -$22.00 by -3.41%, while revenue for the quarter reached $3.87m , beating expectations by +0.78%.
ATRA Stock Performance
Access detailed ATRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
